Literature DB >> 15855017

Effect of oral vaccination of cattle with lipid-formulated BCG on immune responses and protection against bovine tuberculosis.

Bryce M Buddle1, Frank E Aldwell, Margot A Skinner, Geoffrey W de Lisle, Michel Denis, H Martin Vordermeier, R Glyn Hewinson, D Neil Wedlock.   

Abstract

Cattle were given Mycobacterium bovis bacillus Calmette-Guerin (BCG) in a lipid-based formulation via the oral route and tested for immune responses and protection against a challenge with virulent M. bovis. Calves were vaccinated by orally administering a pellet containing 10(8) colony forming units (CFU) of BCG, or 10 pellets containing a total of 10(9) CFU of BCG, whereas positive controls were injected subcutaneously with 10(6) CFU of BCG. All of the subcutaneously vaccinated calves produced positive responses in the caudal fold tuberculin skin test at 8 weeks after vaccination, whereas only 3/9 of the low dose and 6/10 of the high dose orally-vaccinated animals produced positive reactions. None of the animals produced positive reactions to the mycobacterial antigens, ESAT-6 and CFP10 in the interferon-gamma (IFN-gamma) test and only a total of four of the BCG-vaccinated animals produced positive responses in either the standard IFN-gamma or comparative cervical skin test. Oral administration of 10 pellets of lipid-formulated BCG to cattle induced a significant level of protection against bovine tuberculosis compared to that observed in non-vaccinated animals and this level was similar to that seen in the BCG subcutaneously vaccinated animals. Oral vaccination of BCG in a lipid-formulation to calves was shown to induce some positive tuberculin skin test reactions, but could also induce protection against bovine tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15855017     DOI: 10.1016/j.vaccine.2005.01.150

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  19 in total

1.  Assessment of an oral Mycobacterium bovis BCG vaccine and an inactivated M. bovis preparation for wild boar in terms of adverse reactions, vaccine strain survival, and uptake by nontarget species.

Authors:  Beatriz Beltrán-Beck; Beatriz Romero; Iker A Sevilla; Jose A Barasona; Joseba M Garrido; David González-Barrio; Iratxe Díez-Delgado; Esmeralda Minguijón; Carmen Casal; Joaquín Vicente; Christian Gortázar; Alicia Aranaz
Journal:  Clin Vaccine Immunol       Date:  2013-10-30

2.  Is interleukin-4delta3 splice variant expression in bovine tuberculosis a marker of protective immunity?

Authors:  Shelley G Rhodes; Jason Sawyer; Adam O Whelan; Gillian S Dean; Michael Coad; Katie J Ewer; Andreas S Waldvogel; Anthony Zakher; Derek J Clifford; R Glyn Hewinson; H Martin Vordermeier
Journal:  Infect Immun       Date:  2007-03-26       Impact factor: 3.441

3.  Development of luminescent Mycobacterium avium subsp. paratuberculosis for rapid screening of vaccine candidates in mice.

Authors:  Valérie Rosseels; Virginie Roupie; Denise Zinniel; Raúl G Barletta; Kris Huygen
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

4.  Oral vaccination of guinea pigs with a Mycobacterium bovis bacillus Calmette-Guerin vaccine in a lipid matrix protects against aerosol infection with virulent M. bovis.

Authors:  Simon Clark; Martin L Cross; Allan Nadian; Julia Vipond; Pinar Court; Ann Williams; R Glyn Hewinson; Frank E Aldwell; Mark A Chambers
Journal:  Infect Immun       Date:  2008-06-02       Impact factor: 3.441

5.  Induction of Unconventional T Cells by a Mutant Mycobacterium bovis BCG Strain Formulated in Cationic Liposomes Correlates with Protection against Mycobacterium tuberculosis Infections of Immunocompromised Mice.

Authors:  Steven C Derrick; Idalia Yabe; Sheldon Morris; Siobhan Cowley
Journal:  Clin Vaccine Immunol       Date:  2016-07-05

6.  Lack of immune responses to Mycobacterium tuberculosis DosR regulon proteins following Mycobacterium bovis BCG vaccination.

Authors:  May Young Lin; Annemieke Geluk; Steven G Smith; Amanda L Stewart; Annemieke H Friggen; Kees L M C Franken; Marleen J C Verduyn; Krista E van Meijgaarden; Martin I Voskuil; Hazel M Dockrell; Kris Huygen; Tom H M Ottenhoff; Michèl R Klein
Journal:  Infect Immun       Date:  2007-05-14       Impact factor: 3.441

7.  Boosting of cellular immunity against Mycobacterium tuberculosis and modulation of skin cytokine responses in healthy human volunteers by Mycobacterium bovis BCG substrain Moreau Rio de Janeiro oral vaccine.

Authors:  Catherine A Cosgrove; Luiz R R Castello-Branco; Tracy Hussell; Amy Sexton; Rafaela Giemza; Richard Phillips; Andrew Williams; George E Griffin; Gordon Dougan; David J M Lewis
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

8.  Oral vaccination with lipid-formulated BCG induces a long-lived, multifunctional CD4(+) T cell memory immune response.

Authors:  Lindsay R Ancelet; Frank E Aldwell; Fenella J Rich; Joanna R Kirman
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

9.  Vaccination with a BCG strain overexpressing Ag85B protects cattle against Mycobacterium bovis challenge.

Authors:  Caroline Rizzi; María Verónica Bianco; Federico Carlos Blanco; Marcelo Soria; María José Gravisaco; Valeria Montenegro; Lucas Vagnoni; Bryce Buddle; Sergio Garbaccio; Fernando Delgado; Karen Silva Leal; Angel Adrián Cataldi; Odir Antônio Dellagostin; Fabiana Bigi
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

10.  The potential for transmission of BCG from orally vaccinated white-tailed deer (Odocoileus virginianus) to cattle (Bos taurus) through a contaminated environment: experimental findings.

Authors:  Pauline Nol; Jack C Rhyan; Suelee Robbe-Austerman; Matt P McCollum; Tara D Rigg; Nadia T Saklou; Mo D Salman
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.